The Latest
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
So far in 2026 a dozen drugmakers have gone public and raised a median of about $300 million each, a significant spike from previous years.
Updated 6Â hours ago -
Shutterstock / DaveMF
Sponsored by MarkenPrecision under pressure: Logistic solutions for nuclear medicine scalability
Racing the clock: How precision logistics deliver life-saving nuclear medicine.
-
Getty Images
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
Trodelvy's latest setback carries implications for a newly important Merck drug, while the success of a once-weekly HIV tablet could boost Gilead's main business.
-
Courtesy of Treeline Biosciences
Emerging biotechStealthy startup Treeline plans a reverse merger
Led by former Loxo Oncology CEO Josh Bilenker, the startup now has a trio of cancer drugs in early-stage testing and more following closely behind.
-
Courtesy of Johnson & Johnson
Emerging biotechJ&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for $1B
The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.
-
Getty Images
News roundupAstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
Newly published data convinced AstraZeneca to conduct a sprawling late-stage program for its GLP-1 pill. Elsewhere, Bausch + Lomb will lay off 119 employees and Cartesian boosted its ‘in vivo’ cell therapy capabilities.
-
Getty Images
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
While many drugmakers are focused on lung cancer, evidence shows the liver may be a better bet.
-
Getty Images
Emerging biotechCity banks nearly $100M for next-gen RNAi drugs
Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.
-
Getty Images
Tango data add to growing momentum for pancreatic cancer drugs
A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
GSK’s $10.6 billion acquisition of Nuvalent is its third company buyout since late January and the biopharmaceutical sector’s second-largest deal this year.
Updated June 9, 2026 -
Getty Images
Incyte to buy blood disorder drug in possibly $2B deal
Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.
-
Permission granted by Roche
Roche stakes $700M on Nurix’s protein-degrading drug
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
-
Getty Images
China competitionHouse bill aims to crack down on China biotech deals
A proposal to add biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U.S. fears that China’s drugmaking progress may threaten national security.
-
Getty Images
Study data convince Lundbeck to push new migraine drug forward
A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.
-
Fintan Trimble via Getty Images
Generic drugmakers gain key victory in ‘skinny label’ patent case
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
-
ASCO / Nick Agro
ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.
-
Getty Images
News roundup
Otsuka showcases kidney drug data; Pfizer cuts an AI deal
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.
-
Jacob Bell/BioPharma Dive
Alnylam, Inceptive ink AI deal potentially worth $2B
The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.
-
Getty Images
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
-
Getty Images
Emerging biotechLilly, Ascidian link up in RNA exon editing pact
Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.
-
Getty Images
Emerging biotechA Spanish biotech banks $87M to make differentiated ADCs
Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
-
Getty Images
‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
-
Getty Images
An ADC specialist sinks on safety concerns for blood cancer drug
Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”
-
Getty Images
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
-
Getty Images
News roundup
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
-
Getty Images
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
